We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Lifotronic Technology Co., Ltd.

Lifotronic designs, develops, and manufactures medical devices, specializing in bedside treatment and diagnostic prod... read more Featured Products: More products

Download Mobile App





Lifotronic Demonstrates Latest Medical Innovations in Disease Diagnostics

By LabMedica International staff writers
Posted on 06 Feb 2024
Print article
Image: The latest CLIA, HPLC, CBC and POCT solutions showcased at Medlab Middle East 2024 (Photo courtesy of Lifotronic)
Image: The latest CLIA, HPLC, CBC and POCT solutions showcased at Medlab Middle East 2024 (Photo courtesy of Lifotronic)

Lifotronic (Shenzhen, China) is demonstrating its latest medical innovations, including its CLIA, HPLC, CBC, and POCT solutions, at Medlab Middle East 2024.

Lifotronic is presenting a comprehensive range of solutions for large, medium, and small-sized laboratories to a global audience of experts and scholars at the show. Lifotronic’s eCL8000, dubbed the king of emergency, is one of the featured technology products at the exhibition. eCL 8000 is an 86 T/H fully automated analyzer based on the most advanced Electro-chemiluminescence Immunoassay (ECLIA). More than 90 parameters are available, covering thyroid, fertility, tumor, cardiac, inflammation, bone metabolism markers, etc. At Medlab Middle East 2024, Lifotronic is introducing its latest product, the eCL9000 electro-chemiluminescence analyzer which is designed especially for large labs, hospitals, and chain labs. It can perform 300 tests per hour at a constant speed, meeting the high demand of more than 100 samples per day. It also allows end users to easily conduct immunoassay tests. With a super long walkaway time of 5.5 hours, it frees up the operator’s time, improves work efficiency, and creates a more relaxed and flexible work environment.

Lifotronic is also showcasing its latest H100 high-pressure liquid chromatography analyzer which has a test speed of 96s/T. Convenient, fast, and accurate, it also has a one-click switch function for HbA1c and thalassemia modes. H100 can greatly improve the analysis process and achieve the ideal balance of quality, efficiency, and cost. In addition, Lifotronic is highlighting the AC310 and AC610 hematology analyzers which are widely recognized for their stable performance. These analyzers not only provide accurate and reliable clinical data for doctors but also offer patients a higher level of medical services. The AC630 hematology analyzer is the latest addition to the hematology analyzer series and its fully automated operation significantly improves the laboratory’s operational efficiency, as well as brings greater convenience to the operator. Lifotronic is also showcasing its complete solution for POCT using fluorescence immunochromatography and colloidal gold rapid detection. The POCT fluorescence immunochromatography analyzer offers several test parameters, is easy to carry, and enables fast detection. Its single-use cartridge design can satisfy the needs of primary healthcare facilities and small to medium-sized labs with low sample volumes.

Related Links:
Lifotronic

New
Gold Member
Human Chorionic Gonadotropin Test
hCG Quantitative - R012
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Coagulation Analyzer
CS-2400
New
Uric Acid and Blood Glucose Meter
URIT-10

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
MEDLAB 2024
Copyright © 2000-2025 Globetech Media. All rights reserved.